Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market 2020-2029

                                          
This report studies the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market status and forecast, categorizes the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report

  
AbbVie Inc
  
Celgene Corp
  
CTI BioPharma Corp
  
F. Hoffmann-La Roche Ltd
  
Gilead Sciences Inc
  
Incyte Corp
  
Italfarmaco SpA
  
JW Pharmaceutical Corp
  
MedImmune LLC
  
MEI Pharma Inc
  
Merck & Co Inc
  
Novartis AG
  
NS Pharma Inc
  
Promedior Inc
  
Sun Pharma Advanced Research Company Ltd

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering

  
North America
  
Europe

Southeast Asia

  
India
  
China
  
Japan

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

  
United States
  
Canada
  
Mexico

Asia-Pacific

  
India
  
Japan
  
South Korea
  
China
  
Australia
  
Indonesia
  
Singapore
  
Rest of Asia-Pacific

Europe

  
Germany
  
France
  
UK
  
Italy
  
Spain
  
Russia
  
Rest of Europe

Central & South America

  
Brazil
  
Argentina
  
Rest of South America

Middle East & Africa

  
Saudi Arabia
  
Turkey
  
Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

  
Durvalumab
  
Givinostat
  
Glasdegib
  
Idelalisib
  
IMG-7289
  
Others

Key Development

In July 2020, European Commission Approved DAURISMO„¢ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).

Pfizer Inc. (NYSE:PFE) announced that the European Commission approved DAURISMO„¢ (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.

The approval follows the medicines positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) earlier this year, as well as the medicines approval by the U.S. Food and Drug Administration (FDA) in November 2018.

The European Commissions approval of DAURISMO is based on results from the Phase 2 BRIGHT 1003 trial, which showed DAURISMO nearly doubled median overall survival compared to LDAC alone (8.3 months vs. 4.3 months, HR 0.463, 95% CI [0.299,0.717]) in patients with previously untreated (de novo or secondary) AML who were not eligible for intensive chemotherapy. The difference represented a 54 percent reduction in the risk of death for patients treated with DAURISMO plus LDAC (HR: 0.463, 95% CI: 0.299, 0.717, one-sided p-value 0.0002)

DAURISMO in combination with low-dose cytarabine nearly doubled overall survival compared to low-dose cytarabine alone. People with previously untreated acute myeloid leukemia who cannot withstand intensive chemotherapy are in urgent need of new options and using this new therapy that may extend survival for appropriate patients.

DAURISMO is a once-daily oral Hedgehog pathway inhibitor, taken in combination with LDAC. In the EU, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy. In the U.S. and Canada, DAURISMO is approved in combination with LDAC for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

  
Hospital
  
Clinic
  
Others

The study objectives of this report are:

  
To analyze and study the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) capacity, production, value, consumption, status (2015-2019) and forecast (2020-2029);
  
Focuses on the key Post-Polycythemia Vera Myelofibrosis (PPV-MF) manufacturers, to study the capacity, production, value, market share and development plans in future.
  
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.

To define, describe and forecast the market by type, application and region.

  
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
  
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Post-Polycythemia Vera Myelofibrosis (PPV-MF) are as follows:

  
History Year: 2015-2019
  
Base Year: 2019
  
Estimated Year: 2020
  
Forecast Year 2020 to 2029

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

  
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers
  
Post-Polycythemia Vera Myelofibrosis (PPV-MF)
  
Distributors/Traders/Wholesalers
  
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Subcomponent
  
Manufacturers
  
Industry Association
  
Downstream Vendors

Available Customizations

  
Regional and country-level analysis of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, by end-use.
  
Detailed analysis and profiles of additional market players.